Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson's Disease.

Jabeen M, Hameed H, Ahmad SM, Mushtaq T, Khan MA, Hameed A

Open source

DOI
10.1007/s12017-026-08948-3
Published
2026 Aug 31
Container
Neuromolecular medicine
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s12017-026-08948-3,
  title = {Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson's Disease.},
  author = {Jabeen M and Hameed H and Ahmad SM and Mushtaq T and Khan MA and Hameed A},
  year = {2026},
  journal = {Neuromolecular medicine},
  doi = {10.1007/s12017-026-08948-3},
  url = {https://doi.org/10.1007/s12017-026-08948-3}
}

RIS

TY  - JOUR
TI  - Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson's Disease.
AU  - Jabeen M
AU  - Hameed H
AU  - Ahmad SM
AU  - Mushtaq T
AU  - Khan MA
AU  - Hameed A
PY  - 2026
JO  - Neuromolecular medicine
DO  - 10.1007/s12017-026-08948-3
UR  - https://doi.org/10.1007/s12017-026-08948-3
ER  - 

APA

M, J., H, H., SM, A., T, M., MA, K., & A, H. (2026). Rebalancing α-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson's Disease.. Neuromolecular medicine. https://doi.org/10.1007/s12017-026-08948-3

Source records